HARRISON, N.Y., May 22, 2013 /PRNewswire/ -- MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today that the Company will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 in New York City at the Grand Hyatt Hotel. Robert Ladd, President and Chief Executive Officer, will update investors and answer questions.
The Company's presentation is scheduled to begin at 9:30 a.m. EDT. MGT's latest presentation materials as well as its regulatory filings will be available on its website at www.mgtci.com
For more information and registration, please visit the conference website: http://www.marcumllp.com/microcapAbout MGT Capital Investments, Inc. MGT Capital Investments and its subsidiaries are engaged in the business of acquiring, developing and monetizing assets in the online and mobile gaming space. MGT Sports, Inc., a wholly owned subsidiary, owns a majority interest in FanTD LLC, an online daily fantasy sports wagering business. FanTD LLC owns and operates FanThrowdown.com, one of the leading daily fantasy sports websites. Launched in 2012, FanThrowdown.com offers daily fantasy gameplay for the NFL, MLB, NCAA (basketball & football), NHL, NBA and professional golf, with near-term plans to add NASCAR. Its goal is to offer fantasy sports fans the absolute best play environment and the most popular gameplay styles with a perfect balance between user-friendliness and in-depth statistical analysis. MGT Gaming, Inc., a majority owned subsidiary, owns U.S. Patent No. 7,892,088 relating to casino gaming systems. In November 2012, MGT Gaming filed a patent infringement suit against Caesars Entertainment Corporation, MGM Resorts International, Inc., WMS Gaming - a subsidiary of WMS Industries, Inc., Penn National Gaming, Inc., and Aruze Gaming America, Inc. In addition, the Company owns Medicsight, Inc., a medical technology company with intellectual property and operations in imaging software and hardware devices. Medicsight's computer-aided detection software assists radiologists with detection of colorectal polyps, and has received regulatory approvals, including CE Mark and U.S. FDA clearance. Medicsight's assets are presently for sale.